Petra Klappers

1.9k total citations · 2 hit papers
8 papers, 1.4k citations indexed

About

Petra Klappers is a scholar working on Oncology, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Petra Klappers has authored 8 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Pathology and Forensic Medicine and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Petra Klappers's work include CAR-T cell therapy research (7 papers), Acute Lymphoblastic Leukemia research (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Petra Klappers is often cited by papers focused on CAR-T cell therapy research (7 papers), Acute Lymphoblastic Leukemia research (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Petra Klappers collaborates with scholars based in Germany. Petra Klappers's co-authors include Gerhard Zugmaier, Andreas Viardot, Hermann Einsele, Ralf C. Bargou, Peter Kufer, Margit Schmidt, Richard Noppeney, Mariele Goebeler, Stefan Knop and Matthias Klinger and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

Petra Klappers

8 papers receiving 1.3k citations

Hit Papers

Tumor Regression in Cancer Patients by Very Low Doses of ... 2008 2026 2014 2020 2008 2014 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
    2008 798 citations Ralf C. Bargou, Eugen Leo et al. Science profile →
  2. Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
    2014 488 citations Max S. Topp, Nicola Gökbuget et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Petra Klappers Germany 7 989 472 444 418 303 8 1.4k
Mariele Goebeler Germany 10 1.2k 1.2× 545 1.2× 633 1.4× 322 0.8× 299 1.0× 22 1.6k
Svenja Neumann Germany 10 1.1k 1.1× 328 0.7× 377 0.8× 503 1.2× 438 1.4× 12 1.4k
Julia Stieglmaier Germany 15 938 0.9× 301 0.6× 364 0.8× 572 1.4× 387 1.3× 24 1.4k
Matthias Klinger Germany 13 1.4k 1.4× 724 1.5× 684 1.5× 403 1.0× 326 1.1× 23 1.9k
Margit Schmidt Germany 7 715 0.7× 427 0.9× 384 0.9× 222 0.5× 211 0.7× 13 1.0k
Carsten Reinhardt Germany 15 1.0k 1.0× 655 1.4× 723 1.6× 171 0.4× 200 0.7× 37 1.7k
Johannes Duell Germany 18 1.3k 1.3× 482 1.0× 415 0.9× 150 0.4× 571 1.9× 72 1.7k
Ludger Große‐Hovest Germany 19 655 0.7× 281 0.6× 712 1.6× 83 0.2× 61 0.2× 46 1.2k
Dorothea Wessiepe Germany 5 497 0.5× 160 0.3× 198 0.4× 237 0.6× 126 0.4× 5 669
Hervé Dombret France 9 567 0.6× 81 0.2× 190 0.4× 542 1.3× 243 0.8× 14 1.1k

Countries citing papers authored by Petra Klappers

Since Specialization
Citations

This map shows the geographic impact of Petra Klappers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petra Klappers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petra Klappers more than expected).

Fields of papers citing papers by Petra Klappers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petra Klappers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petra Klappers. The network helps show where Petra Klappers may publish in the future.

Co-authorship network of co-authors of Petra Klappers

This figure shows the co-authorship network connecting the top 25 collaborators of Petra Klappers. A scholar is included among the top collaborators of Petra Klappers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petra Klappers. Petra Klappers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Topp, Max S., Nicola Gökbuget, Gerhard Zugmaier, et al.. (2014). Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 32(36). 4134–4140. 488 indexed citations breakdown →
2.
Topp, Max S., Nicola Goekbuget, Gerhard Zugmaier, et al.. (2012). Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL.. Journal of Clinical Oncology. 30(15_suppl). 6500–6500. 15 indexed citations
3.
4.
Topp, Max S., Nicola Goekbuget, Gerhard Zugmaier, et al.. (2011). Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial. Blood. 118(21). 252–252. 26 indexed citations
5.
6.
Nagorsen, Dirk, Gerhard Zugmaier, Andreas Viardot, et al.. (2009). Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m2/d of BiTE® Antibody Blinatumomab.. Blood. 114(22). 2723–2723. 6 indexed citations
7.
Bargou, Ralf C., Peter Kufer, Mariele Goebeler, et al.. (2008). Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL. Blood. 112(11). 267–267. 6 indexed citations
8.
Bargou, Ralf C., Eugen Leo, Gerhard Zugmaier, et al.. (2008). Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody. Science. 321(5891). 974–977. 798 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mariele Goebeler Breakdown of academic impact, for papers by Svenja Neumann Breakdown of academic impact, for papers by Julia Stieglmaier Breakdown of academic impact, for papers by Matthias Klinger Breakdown of academic impact, for papers by Margit Schmidt Breakdown of academic impact, for papers by Carsten Reinhardt Breakdown of academic impact, for papers by Johannes Duell Breakdown of academic impact, for papers by Ludger Große‐Hovest Breakdown of academic impact, for papers by Dorothea Wessiepe Breakdown of academic impact, for papers by Hervé Dombret
Rankless by CCL
2026